November 12-14, 2019 - Shanghai
The annual CHINATRIALS Summit has established itself as the must-attend industry-focused event for global clinical development executives in China. You will meet hundreds of new contacts as you network with over 400 of your global clinical peers. CHINATRIALS draws the highest ratio of pharmaceutical/biotech attendees of any Asia-focused clinical development conference and is the only clinical event you need to attend this year to stay updated on China’s fast-moving clinical development industry.
Launched in 2008, CHINATRIALS brings together 400 senior-level clinical development executives from established and newly formed multinational and domestic pharmaceutical and biotechs companies.
November 18-20, 2019 - Shanghai
BioCentury and BayHelix Present: The 6th China Healthcare Summit. The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting.
Launched in 2014, BioCentury China Healthcare Summit brings together 400 attendees each year for unparalleled networking between industry, academia and finance
March 24-26, 2020 - Shanghai
Organized by the non-profit Consortium of China Healthcare and run entirely by a network of well-connected volunteers, China Healthcare Investment Conference (CHIC) is the premier and longest running event of its kind in China. The conference brings together those company executives, entrepreneurs, investors, services providers and government officials interested in and committed to the development of the China healthcare industry.
Launched in 2010, CHIC brings together 550 attendees each year.
March 24-26, 2020 - Shanghai
Healthcare Capital and Connections Summit (HCCS) is an exclusive three-day, invitation-only opportunity to connect with the most relevant healthcare VCs, startups, large corporate and business partners in the China market.
The founding sponsors, Silicon Valley Bank, SPD Silicon Valley Bank, Piper Jaffray, Vivo Capital and AdvaMed, have created a unique Summit format focused on helping companies make deals happen.
Launched in 2014, HCCS brings together a targeted 200 attendees from China and around the globe, carefully selected to provide high-quality interactions.
April 14, 2020 - Tokyo
Co-Organized with the Medical Affairs Professional Society, the 3rd MAPS Japan Medical Affairs Summit has grown into the most influential annual gathering for Japan’s medical affairs professionals. New regulatory compliance directives continue to challenge the traditional commercial-driven business environment in Japan and a main goal of the Summit is to help break down the barriers between medical and commercial departments. The conference draws attendees from all levels- not only from the medical department, but also from other internal stakeholders including R&D, commercial and policy departments.
Launched in 2018, the event draws over 100 attendees each year.
June 16-17, 2020 - Shanghai
Now in its 7th year, MAPS China Medical Affairs Summit is the longest-running and most influential global event for China’s medical affairs professionals. Co-organized with the Medical Affairs Professional Society, the conference brings together professionals from junior to senior level, mostly from China but with significant representation from US/EU senior level professionals. This local and global mix ensures a great atmosphere for sharing best practices and the latest strategic thinking on key topics driving the role of medical affairs professionals worldwide.
Launched in 2013, the event draws 200 attendees each year.
End of July 2020 - Boston
CHINATRIALS+US brings together 100+ senior clinical development executives from Chinese innovative biotechs interested in conducting clinical trials in the US and US biotechs who have interest conducting clinical trials in or entering the China market.
The focus of discussion will be on the strategic and technical considerations these companies should consider when entering the US or China markets. We hope the synergies of bringing these two important groups together will introduce new opportunities for partnerships and collaborations for parallel drug dev